- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
First Quarter
This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.
| Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
|---|---|---|---|---|---|
| Amitiza | Takeda | Lubiprostone | Par | Used to treat chronic idiopathic constipation, as well as opioid-induced constipation in adult with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation. The drug is also used to treat irritable bowel syndrome with constipation in women at least 18 years old | 1/4/2021 |
| Firazyr | Takeda | icatibant | Apotex | Used to treat acute attacks of hereditary angioedema |
1/6/2021 |
| Zytiga | Johnson & Johnson | abiraterone | Amneal | Used to treat metastatic prostate cancer | 1/8/2021 |
| Uloric | Takeda | febuxostat | Dr. Reddy's Labs | Used for the chronic management of hyperuricemia in adult patients with gout |
1/11/2021 |
| Tecfidera | Biogen | dimethyl fumarate | TWi | Used to treat relapsing forms of multiple sclerosis | 1/11/2021 |
| Albenza | Amneal | albendazole | Cost Plus | Used to treat parasitic infections such as hydatid disease and neurocysticercosis | 1/14/2021 |
| NuvaRing | Merck | etonogestrel / ethyl estradiol | Teva | Used by women to prevent pregnancy | 1/14/2021 |
| Effexor XR | Wyeth | venlafaxine | Hetero | Used to treat major depressive disorder, anxiety, and panic disorder | 1/21/2021 |
| Minipress | Pfizer | prazosin | ANI | Used to treat hypertension, to lower blood pressure | 2/1/2021 |
| Sabril | Lundbeck | vigabatrin | Dr. Reddy's Labs | Used to treat refractory complex partial seizures and infantile spasms | 2/2/2021 |
| Thorazine | Glaxo | chlorpromazine | Lannett | Used to treat psychotic disorders such as schizophrenia or manic-depression in adults | 2/8/2021 |
| AndroGel 1.62% | Unimed | testosterone | Teva | Used for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone | 2/12/2021 |
| Noxafil | Merck | posaconazole | Lupin | Used for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy | 2/17/2021 |
| Xeloda | Roche | capecitabine | Dr. Reddy's Labs | Used to treat adjuvant colon cancer, metastatic colorectal & breast cancer | 2/17/2021 |
| Northera | Lundbeck | droxidopa | Hetero | Used to treat symptoms of low blood pressure when standing, caused by a certain medical condition (neurogenic orthostatic hypotension-NOH) | 2/19/2021 |
| Prevacid SoluTab | Takeda | lansoprazole | Dr. Reddy's | Used to treat certain stomach and esophagus problems (such as acid reflux, ulcers) | 2/22/2021 |
| Northera | Lundbeck | droxidopa | Hikma | Used to treat symptoms of low blood pressure when standing, caused by a certain medical condition (neurogenic orthostatic hypotension-NOH) | 3/2/2021 |
| Depen | Mylan | penicillamine | Lupin | Usedto treat Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy | 3/2/2021 |
| Azopt | Novartis | brinzolamide | Teva | Used to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma | 3/8/2021 |
| Alinia | Romark | nitazoxamide | Lupin | Used in the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older | 3/10/2021 |
| Foscavir | Teva | foscarnet | Fresenius Kabi | Used to treat CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and in Combination therapy with Foscarnet Sodium Injection and ganciclovir for patients who have relapsed after monotherapy with either drug | 3/15/2021 |
| Lopid | Pfizer | gemfibrozil | Hetero | Used together with proper diet to treat very high cholesterol and triglyceride levels and raise “good” cholesterol (HDL) in the blood | 3/30/2021 |
GENERICally Speaking Spring 2021
Related Professionals
GENERICally Speaking Spring 2021
Spring 2021 Related Publications
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2022
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
August 2, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.